TGF-β Signaling in Cancer: Mechanisms of Progression and Therapeutic Targets
International Journal of Molecular Sciences · 29.07.2025 · 26 (15) · 7326
DOI: 10.3390/ijms26157326 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.07.2025. Verfasst von Elżbieta Cecerska-Heryć und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Pomeranian Medical University of Szczecin, Powstancow Wielkopolskich 72, 70-111 Szczecin, Poland. Hauptthemen laut MEDLINE: Transforming Growth Factor beta, Neoplasms, Signal Transduction. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pomeranian Medical University in Szczecin.
Abstract (Originalsprache)
Transforming growth factor-β (TGF-β) is a key protein family member that includes activins, inhibins, and bone morphogenetic proteins (BMPs). It is essential in numerous biological processes, such as chemotaxis, apoptosis, differentiation, growth, and cell migration. TGF-β receptors initiate signaling through two primary pathways: the canonical pathway involving Smad proteins and non-canonical pathways that utilize alternative signaling mechanisms. When TGF-β signaling is disrupted, it has been shown to contribute to the development of various diseases, including cancer. Initially, TGF-β effectively inhibits the cell cycle and promotes apoptosis. However, its role can transition to facilitating tumor growth and metastasis as the disease progresses. Moreover, TGF-β drives cancer progression through epithelial–mesenchymal transition (EMT), modulation of factor expression, and evasion of immune responses. This complexity establishes the need for further research, particularly into pharmacological agents targeting TGF-β, which are emerging as promising therapeutic options. Current clinical and preclinical studies are making significant strides toward mitigating the adverse effects of TGF-β. This underscores the critical importance of understanding its underlying mechanisms to enhance treatment effectiveness and improve survival rates for cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Pomeranian Medical University of Szczecin, Powstancow Wielkopolskich 72, 70-111 Szczecin, Poland.
- Department of Immunological Diagnostics, Pomeranian Medical University of Szczecin, Powstancow Wielkopolskich 72, 70-111 Szczecin, Poland.
ORCID-Profile: Elżbieta Cecerska-Heryć, Natalia Serwin, Bartosz Wojciuk, Barbara Dołęgowska
Förderung
- Pomeranian Medical University in Szczecin
Zitieren
APA
Cecerska-Heryć, E., Jerzyk, A., Goszka, M., Polikowska, A., Rachwalska, J., Serwin, N., Wojciuk, B., & Dołęgowska, B. (2025). TGF-β Signaling in Cancer: Mechanisms of Progression and Therapeutic Targets. International Journal of Molecular Sciences, 26(15), 7326. https://doi.org/10.3390/ijms26157326
Vancouver
Cecerska-Heryć E, Jerzyk A, Goszka M, Polikowska A, Rachwalska J, Serwin N, et al. TGF-β Signaling in Cancer: Mechanisms of Progression and Therapeutic Targets. International Journal of Molecular Sciences. 2025;26(15):7326. doi:10.3390/ijms26157326
BibTeX
@article{CecerskaHery2025,
author = {Cecerska-Heryć, Elżbieta and Jerzyk, Adrianna and Goszka, Małgorzata and Polikowska, Aleksandra and Rachwalska, Julita and Serwin, Natalia and Wojciuk, Bartosz and Dołęgowska, Barbara},
title = {TGF-β Signaling in Cancer: Mechanisms of Progression and Therapeutic Targets},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {15},
pages = {7326},
doi = {10.3390/ijms26157326}
}
EUVIMED